Caricamento...
Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma
Purpose: There is limited standard treatment for patients with advanced cholangiocarcinoma after refractory of chemotherapy. Apatinib is a tyrosine kinase inhibitor targeting VEGFR-2, which exhibited broad-spectrum antitumor activities in previous studies. We aim to evaluate the efficacy and safety...
Salvato in:
| Pubblicato in: | J Cancer |
|---|---|
| Autori principali: | , , , , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Ivyspring International Publisher
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7847639/ https://ncbi.nlm.nih.gov/pubmed/33532001 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.53482 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|